We strongly support NJ Senate Bill 3818/Assembly Bill 5217 which ensures that health insurers accept and count payments made on behalf of patients toward their deductibles and out-of-pocket maximums.
We are in strong support of HAB’s proposal included in the Federal Register on November 10, 2025, to update the funding formulas used by the Ryan White HIV/AIDS Program (RWHAP) for allocating Part A and Part B funding. This welcome change is long overdue and will increase equity in the distribution of funding and better match the level of funding with the number of RWHAP clients residing in a jurisdiction.
We joined with the Arthritis Foundation on a letter signed by 20 patient groups to HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Dr. Oz regarding TrumpRx, thanking them for their efforts for lowering Rx costs, but highlighting the need to ensure that patients are aware that their costs do not count towards their insurance requirements and cost-sharing.
We write in strong support of the PrEP DC Act of 2025 (B26-0159) and urge the Committee on Business and Economic Development, which has shared jurisdiction over the bill, to approve this legislation as soon as possible.
The HIV+Hepatitis Policy Institute strongly urges the Advisory Committee on Immunization Practices (ACIP) to maintain the recommendation of a universal hepatitis B birth dose in the United States. Maintaining this requirement will not only help prevent people from becoming ill but result in ending hepatitis B in our country, which is still a highly infectious disease.